Phaeosynt erzielt 1,8 Mio. in Seed-Finanzierung – Vorreiter in tierfreier, nachhaltiger Antikörperproduktion

Phaeosynt, a trailblazer in sustainable biotechnology, is thrilled to announce the successful raise of 1,800,000 in funding. This exciting milestone not only reinforces investor confidence in the company’s innovative approach but also paves the way for significant advancements in the production of antibodies. Traditionally, antibodies are derived from animals—a process that tragically results in the death of over half a million animals in the EU annually—and often relies on animal cell cultures that depend on animal-based media, leading to high emissions and quality inconsistencies. With a clear vision to enhance sustainability and environmental protection, Phaeosynt has developed a groundbreaking process that produces the very first antibodies from diatoms (Kieselalgen). By harnessing the unique capabilities of these microalgae, Phaeosynt offers a truly animal-free alternative to conventional antibodies. This revolutionary method not only eliminates ethical concerns associated with animal suffering but also ensures that production remains consistent, high-quality, and not subject to the vagaries of animal health. The funding will be strategically utilized to further optimize and scale up this process, allowing the company to refine its production pipeline to industrial levels. In doing so, Phaeosynt is not only addressing environmental challenges by reducing carbon emissions inherent in traditional antibody production but is also opening up exciting new opportunities for customers. These include cost benefits, enhanced product reliability, and the potential to develop entirely new product lines that adhere to vegan principles. Ultimately, this investment marks a significant step forward in the pursuit of a climate-neutral and animal-friendly biotechnological future.